Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer.
Lebok P, Roming M, Kluth M, Koop C, Özden C, Taskin B, Hussein K, Lebeau A, Witzel I, Wölber L, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Müller V, Schmalfeldt B, Simon R, Sauter G, Terracciano L, Krech RH, von der Assen A, Burandt E. Lebok P, et al. Among authors: schmalfeldt b. Oncotarget. 2016 Dec 6;7(49):81322-81331. doi: 10.18632/oncotarget.13227. Oncotarget. 2016. PMID: 27835607 Free PMC article.
Role of HYAL1 expression in primary breast cancer in the formation of brain metastases.
Witzel I, Marx AK, Müller V, Wikman H, Matschke J, Schumacher U, Stürken C, Prehm P, Laakmann E, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L. Witzel I, et al. Among authors: schmalfeldt b. Breast Cancer Res Treat. 2017 Apr;162(3):427-438. doi: 10.1007/s10549-017-4135-6. Epub 2017 Feb 6. Breast Cancer Res Treat. 2017. PMID: 28168629
[Current Status of Targeted Treatment in Breast Cancer].
Seiffert K, Schmalfeldt B, Müller V. Seiffert K, et al. Among authors: schmalfeldt b. Dtsch Med Wochenschr. 2017 Nov;142(22):1669-1675. doi: 10.1055/s-0043-108468. Epub 2017 Oct 27. Dtsch Med Wochenschr. 2017. PMID: 29078212 German.
Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer.
Prieske K, Prieske S, Joosse SA, Trillsch F, Grimm D, Burandt E, Mahner S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L, Woelber L. Prieske K, et al. Among authors: schmalfeldt b. Oncotarget. 2017 Sep 15;8(47):83063-83074. doi: 10.18632/oncotarget.20945. eCollection 2017 Oct 10. Oncotarget. 2017. PMID: 29137324 Free PMC article.
Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients.
Oliveira-Ferrer L, Goswami R, Galatenko V, Ding Y, Eylmann K, Legler K, Kürti S, Schmalfeldt B, Milde-Langosch K. Oliveira-Ferrer L, et al. Among authors: schmalfeldt b. Dis Markers. 2018 Jun 28;2018:6714287. doi: 10.1155/2018/6714287. eCollection 2018. Dis Markers. 2018. PMID: 30050594 Free PMC article.
192 results